Omar Noor, MD, FAAD

Omar Noor, MD, outlines the complex phenotypes, variable presentations, and functional burdens of chronic hand eczema and explains why a broader JAK-targeted strategy may offer therapeutic advantages.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, led NP and PA attendees through 3 complex cases of atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

An expert discusses how successful psoriasis management requires patient-centered care, shared decision-making, matching therapy to individual patient needs rather than just the disease, and ongoing communication to ensure treatment adherence and success.

An expert discusses how treating busy professionals with scalp and nail psoriasis involves addressing injection anxiety, treatment adherence challenges, and the emotional impact of visible disease through health care provider–administered biologics.

An expert how managing psoriasis in active travelers requires considering dosing frequency, insurance transitions from commercial to Medicare coverage, and selecting biologics with longer intervals between treatments.

An expert discusses how treating older patients with psoriasis, such as a 72-year-old retired teacher, requires addressing cognitive decline, dexterity issues, and comorbidities by considering in-office biologic administration and buy-and-bill processes for Medicare accessibility.

An expert discusses how managing psoriasis requires personalizing treatment based on patient adherence challenges, access issues, comorbidities such as depression, and practical considerations such as injection comfort and frequency.

Omar Noor, MD, FAAD, explores the complex immune and cellular mechanisms behind CHE and highlights its significant physical and emotional toll on patients.

Biologic coordinators play a key role in managing insurance approvals and ensuring coverage details are confirmed quickly, often within 48 hours.

Noor noted patients benefit from in-house injection services, avoiding the inconvenience of traveling to off-site centers.

Noor emphasizes that patient access is the primary consideration when deciding to use the buy-and-bill model.

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.

At the inaugural Horizons in Advanced Practice meeting, Dr. Noor highlighted the value of amplifying the voices of physician assistants and nurse practitioners to advance patient care.

Omar Noor, MD, FAAD, hosted a live Case-Based Roundtable discussion with local dermatology clinicians to discuss 2 patients with plaque psoriasis and what would be the ideal topical treatment for each.

An expert dermatologist examines the efficacy and potential of tapinarof cream, a novel non-steroidal topical treatment, in providing long-term relief for patients with plaque psoriasis.

A dermatologist explores strategies for managing adverse events in psoriasis treatment, with a specific focus on considerations and best practices for patients with skin of color.

An expert dermatologist explores personalized psoriasis treatment strategies, emphasizing patient education on realistic treatment response expectations and proper application techniques to enhance therapeutic efficacy.

A board-certified dermatologist examines evidence-based strategies for managing plaque psoriasis, focusing on personalized non-steroidal treatment options to optimize patient outcomes.

Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.

Noor, the co-owner of Rao Dermatology, shares about his interests in dermatology and what he most looks forward to as a member of our board.

Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.

Omar Noor, MD, FAAD, discusses the critical role of patient education and transparent communication in the context of treating individuals with atopic dermatitis. He emphasizes the significance of cultivating trust in patient-provider relationships, explores the potential necessity of shifting the treatment paradigm, and addresses the implications of treatment interruptions or transitions in the long-term management of this condition, all while considering the crucial aspect of access to care.

Omar Noor, MD, FAAD, discusses cultural competency in caring for patients with skin of color in dermatology.

Omar Noor, MD, FAAD, discusses his SDPA session, "Clinical Pearls for Pediatric and Adult Dermatology."

Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.

Three dermatologists discuss the case of an 18-year-old patient with AD who is exploring nonsteroidal options to manage his disease.

Drs Noor and Bhatia have a conversation about cost and financial assistance from pharmaceutical companies.

Drs Bhatia and Lamb discuss the case of a 12-year-old child with asthma and how they would manage his disease.